The data are presented as mean (SD). Differences in the response of healthy subjects to hypoxia were analyzed by repeated-measures ANOVA, with drug as a within-subject factor and order as a between-subject factor.
Changes from baseline to week 12 in the primary end point (mean PAP) and the secondary end points (PVR, CO, physical symptom score, and 6MW) were compared between the sildenafil and placebo groups using analysis of variance (ANOVA). The differences among all three treatment groups were compared using ANOVA. If a significant difference was observed among the three treatment groups, comparisons of each treatment group with placebo were conducted. In addition, the combined sildenafil dose groups (sildenafil 25 mg 8 hourly and 100 mg 8 hourly) were compared with placebo by ANOVA.
Was this article helpful?